Pancreatic cancer: BRCA mutation and personalized treatment

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29
   PubMed Web of Science ®Google Scholar
• Long J, Luo GP, Xiao ZW, et al. Cancer statistics: current diagnosis and treatment of pancreatic cancer in Shanghai, China. Cancer Lett 2014;346:273-7
   PubMed Web of Science ®Google Scholar
• Oettle H. Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside. Cancer Treat Rev 2014;40:1039-47
   PubMed Web of Science ®Google Scholar
• Shi S, Yao W, Xu J, et al. Combinational therapy: new hope for pancreatic cancer? Cancer Lett 2012;317:127-35
   PubMed Web of Science ®Google Scholar
• Olowokure O, Qi X. Pancreatic cancer: current standards, working towards a new therapeutic approach. Expert Rev Anticancer Ther 2014;14:495-7
   PubMed Web of Science ®Google Scholar
• Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17
   PubMed Web of Science ®Google Scholar
• Luo G, Long J, Zhang B, et al. Stroma and pancreatic ductal adenocarcinoma: an interaction loop. Biochim Biophys Acta 2012;1826:170-8
   PubMed Web of Science ®Google Scholar
• Jiang JH, Liu C, Cheng H, et al. Epithelial-mesenchymal transition in pancreatic cancer: Is it a clinically significant factor? Biochim Biophys Acta 2015;1855:43-9
   PubMed Web of Science ®Google Scholar
• Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006;25:5864-74
   PubMed Web of Science ®Google Scholar
• Thull DL, Vogel VG. Recognition and management of hereditary breast cancer syndromes. Oncologist 2004;9:13-24
   PubMed Web of Science ®Google Scholar
• Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004;4:665-76
   PubMed Web of Science ®Google Scholar
• Prat J, Ribe A, Gallardo A. Hereditary ovarian cancer. Hum Pathol 2005;36:861-70
   PubMed Web of Science ®Google Scholar
• Cho JH, Bang S, Park SW, et al. BRCA2 mutations as a universal risk factor for pancreatic cancer has a limited role in Korean ethnic group. Pancreas 2008;36:337-40
   PubMed Web of Science ®Google Scholar
• Bhattacharyya A, Ear US, Koller BH, et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000;275:23899-903
   PubMed Web of Science ®Google Scholar
• Tassone P, Tagliaferri P, Perricelli A, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003;88:1285-91
   PubMed Web of Science ®Google Scholar
• Kwa M, Edwards S, Downey A, et al. Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin. Ann Surg Oncol 2014;21:1468-73
   PubMed Web of Science ®Google Scholar
• Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008;451:1116-20
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-17
   PubMed Web of Science ®Google Scholar
• Clark CC, Weitzel JN, O’Connor TR. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol Cancer Ther 2012;11:1948-58
   PubMed Web of Science ®Google Scholar
• Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol 2014;25:32-40
   PubMed Web of Science ®Google Scholar
• Greer JB, Whitcomb DC. Role of BRCA1 and BRCA2 mutations in pancreatic cancer. Gut 2007;56:601-5
   PubMed Web of Science ®Google Scholar
• Schutte M, da Costa LT, Hahn SA, et al. Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc Natl Acad Sci USA 1995;92:5950-4
   PubMed Web of Science ®Google Scholar
• Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56:5360-4
   PubMed Web of Science ®Google Scholar
• Ozcelik H, Schmocker B, Di Nicola N, et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 1997;16:17-18
   PubMed Web of Science ®Google Scholar
• Figer A, Irmin L, Geva R, et al. The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. Br J Cancer 2001;84:478-81
   PubMed Web of Science ®Google Scholar
• Oddoux C, Struewing JP, Clayton CM, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996;14:188-90
   PubMed Web of Science ®Google Scholar
• Lowery MA, Kelsen DP, Stadler ZK, et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist 2011;16:1397-402
   PubMed Web of Science ®Google Scholar
• Sonnenblick A, Kadouri L, Appelbaum L, et al. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biol Ther 2011;12:165-8
   PubMed Web of Science ®Google Scholar
• Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-51
   PubMed Web of Science ®Google Scholar
• Drew Y, Mulligan EA, Vong WT, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 2011;103:334-46
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34
   PubMed Web of Science ®Google Scholar
• O’Sullivan CC, Moon DH, Kohn EC, Lee JM. Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors. Front Oncol 2014;4:42
   PubMedGoogle Scholar
• Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:1365-72
   PubMed Web of Science ®Google Scholar
• Iqbal J, Ragone A, Lubinski J, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2012;107:2005-9
   PubMed Web of Science ®Google Scholar
• Mersch J, Jackson MA, Park M, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 2015;121:269-75
   PubMed Web of Science ®Google Scholar
• Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94:1358-65
   PubMed Web of Science ®Google Scholar
• Axilbund JE, Argani P, Kamiyama M, et al. Absence of germline BRCA1 mutations in familial pancreatic cancer patients. Cancer Biol Ther 2009;8:131-5
   PubMed Web of Science ®Google Scholar
• Couch FJ, Johnson MR, Rabe KG, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007;16:342-6
   PubMed Web of Science ®Google Scholar
• Dagan E. Predominant Ashkenazi BRCA1/2 mutations in families with pancreatic cancer. Genet Test 2008;12:267-71
   PubMedGoogle Scholar
• Ghiorzo P, Pensotti V, Fornarini G, et al. Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy. Fam Cancer 2012;11:41-7
   PubMed Web of Science ®Google Scholar
• Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003;95:214-21
   PubMed Web of Science ®Google Scholar
• Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002;62:3789-93
   PubMed Web of Science ®Google Scholar
• Zhen DB, Rabe KG, Gallinger S, et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med 2015;17:569-77
   PubMed Web of Science ®Google Scholar
• Ferrone CR, Levine DA, Tang LH, et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol 2009;27:433-8
   PubMed Web of Science ®Google Scholar
• Lucas AL, Shakya R, Lipsyc MD, et al. High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clin Cancer Res 2013;19:3396-403
   PubMed Web of Science ®Google Scholar
• Huang L, Wu C, Yu D, et al. Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer. Carcinogenesis 2013;34:1001-5
   PubMed Web of Science ®Google Scholar
• Petersen GM, Hruban RH. Familial pancreatic cancer: where are we in 2003? J Natl Cancer Inst 2003;95:180-1
   PubMed Web of Science ®Google Scholar
• Tersmette AC, Petersen GM, Offerhaus GJ, et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001;7:738-44
   PubMed Web of Science ®Google Scholar
• Rustgi AK. Familial pancreatic cancer: genetic advances. Genes Dev 2014;28:1-7
   PubMed Web of Science ®Google Scholar
• Mocci E, Milne RL, Mendez-Villamil EY, et al. Risk of pancreatic cancer in breast cancer families from the breast cancer family registry. Cancer Epidemiol Biomarkers Prev 2013;22:803-11
   PubMed Web of Science ®Google Scholar
• Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310-16
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21
   PubMed Web of Science ®Google Scholar
• Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010;10:293-301
   PubMed Web of Science ®Google Scholar
• Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 2011;5:387-93
   PubMed Web of Science ®Google Scholar
• Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-44
   PubMed Web of Science ®Google Scholar
• Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res 2012;72:5588-99
   PubMed Web of Science ®Google Scholar
• Chen S, Wang G, Niu X, et al. Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. Cancer Lett 2014;348:20-8
   PubMed Web of Science ®Google Scholar
• Yuan K, Sun Y, Zhou T, et al. PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy. Clin Cancer Res 2013;19:4750-9
   PubMed Web of Science ®Google Scholar
• McCabe N, Lord CJ, Tutt AN, et al. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther 2005;4:934-6
   PubMed Web of Science ®Google Scholar
• Wang Y, Kuramitsu Y, Tokuda K, et al. Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer. PLoS One 2014;9:e109076
   Google Scholar
• Jacob DA, Bahra M, Langrehr JM, et al. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells. J Gastroenterol Hepatol 2007;22:738-48
   PubMed Web of Science ®Google Scholar
• Bunting SF, Callen E, Wong N, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010;141:243-54
   PubMed Web of Science ®Google Scholar
• Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008;451:1111-15
   PubMed Web of Science ®Google Scholar
• Porcelli L, Quatrale AE, Mantuano P, et al. Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Mol Oncol 2013;7:308-22
   PubMed Web of Science ®Google Scholar
• Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946-52
   PubMed Web of Science ®Google Scholar
• Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia Meridionale. Cancer 2002;94:902-10
   PubMed Web of Science ®Google Scholar
• Colucci G, Labianca R, Di Costanzo F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010;28:1645-51
   PubMed Web of Science ®Google Scholar
• Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015;518:495-501
   PubMed Web of Science ®Google Scholar
• Tran BMS, Zogopoulos G, Borgida A, et al. Platinum-based chemotherapy (pt-chemo) in pancreatic adenocarcinoma (pc) associated with brca mutations: A translational case series. J Clin Oncol 2012;Abstract 217
   Google Scholar
• Oliver GR, Surgar E, Laheru D, Diaz LA. Family history of cancer and sensitivity to platinum chemotherapy in pancreatic adenocarcinoma. Gastrointestinal Cancers Symposium 2010: Abstract 180
   Google Scholar
• Golan T, Kanji ZS, Epelbaum R, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 2014;111:1132-8
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-61
   PubMed Web of Science ®Google Scholar
• Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008;105:17079-84
   PubMed Web of Science ®Google Scholar
• O’Reilly EM, Lowery MA, Segal MF, et al. Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC). ASCO meet 2014: Abstract 4023
   Google Scholar
• Pishvaian MJ, Wang H, Zhuang T, et al. A phase I/II study of ABT-888 in combination with 5-fluorouracil (5-FU) and oxaliplatin (Ox) in patients with metastatic pancreatic cancer (MPC). ASCO Meet 2013: Abstract 147
   Google Scholar
• Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: an open-label phase II study. ASCO Meet 2013: Abstract 11024
   Google Scholar
• Chalasani P, Kurtin S, Dragovich T. Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation. JOP 2008;9:305-8
   PubMedGoogle Scholar
• James E, Waldron-Lynch MG, Saif MW. Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs 2009;20:634-8
   PubMed Web of Science ®Google Scholar
• Beger C, Ramadani M, Meyer S, et al. Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma. Clin Cancer Res 2004;10:3780-7
   PubMed Web of Science ®Google Scholar
• Fogelman DR, Wolff RA, Kopetz S, et al. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res 2011;31:1417-20
   PubMed Web of Science ®Google Scholar
• Oliver GR, Surgar E, Laheru D, Diaz LA. Family history of cancer and sensitivity to platinum chemotherapy in pancreatic adenocarcinoma. Gastrointestinal Cancers Symposium 2010: Abstract 180
   Google Scholar
• A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. Available from: https://clinicaltrials.gov/ct2/show/NCT02042378
   Google Scholar
• Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01585805
   Google Scholar
• ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01489865
   Google Scholar
• Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (POLO). Available from: https://clinicaltrials.gov/ct2/show/NCT02184195
   Google Scholar
• Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01296763
   Google Scholar
• Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT01286987
   Google Scholar